人类表皮生长因子受体2/neu基因在胆道系统恶性肿瘤中的研究进展  

Recent advances of human epidermal growth factor receptor 2/neu in biliary tract carcinoma

作　　者：包润发[1] 束翌俊 刘颖斌[1] 

机构地区：[1]上海交通大学医学院附属新华医院普通外科上海交通大学医学院胆道疾病研究所,200092

出　　处：《中华消化外科杂志》2015年第5期434-437,共4页Chinese Journal of Digestive Surgery

基　　金：国家自然科学基金面上项目（81172029,81272402）

摘　　要：胆道系统恶性肿瘤是消化系统较常见的恶性肿瘤.由于缺乏典型临床表现及有效的早期诊断方法,多数患者发现时已是晚期,失去了手术机会.现有的放化疗手段对胆道系统恶性肿瘤收效甚微.因此,亟需探索治疗胆道系统恶性肿瘤的新手段.人类表皮生长因子受体2（HER2）/neu基因编码蛋白是一种具有酪氨酸激酶活性的跨膜糖蛋白,在胆道系统恶性肿瘤的发生、发展和侵犯转移过程中发挥着重要作用.HER2/neu基因高表达与胆道系统恶性肿瘤患者临床病理因素及预后密切相关,有望作为肿瘤治疗的新靶点.Biliary tract carcinoma （BTC） is a common malignancy in human digestive system.The lethality of BTC is essentially attributed to the asymptomatic growth of BTC and the lack of effective diagnostic options.The disease is therefore usually detected at an advanced stage and lost the opportunity of surgical therapy.Conventional chemotherapy and radiation therapy have been notably ineffective against BTC.There is now a real and urgent need to focus on developing novel and potent therapeutic strategies against BTC.Human epidermal growth factor receptor 2/neu （HER2/neu） is a member of the ErbB receptor tyrosine kinase family.HER2/neu is associated with tumor proliferation,invasion,and metastasis that would impact in a significant way on clinical outcome.HER/neu may become a new therapy target of BTC.

关 键 词：胆道肿瘤 恶性 人类表皮生长因子受体2/neu 治疗 

分 类 号：R735.8[医药卫生—肿瘤]